EUVIMEDEUVIMED entdecken
Editorial

Increased Doses of Adalimumab are Associated With Clinical Improvement of Hidradenitis Suppurativa

Jazzmin Williams, Claudia Guzik, Akhil Wadhera, Haley Naik

Journal of Drugs in Dermatology · 01.06.2023 · 22 (6) · 615-618

DOI: 10.36849/jdd.6868 ↗

Kurz gefasst

Editorial in der Zeitschrift Journal of Drugs in Dermatology, online erschienen am 01.05.2023. Verfasst von Jazzmin Williams und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa. Die Arbeit wurde bisher 14-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaHumansAdalimumabRetrospective StudiesOverweightTumor Necrosis Factor InhibitorsSeverity of Illness IndexObesityTreatment Outcome

Substanzen

AdalimumabTumor Necrosis Factor Inhibitors

Zitieren

APA

Williams, J., Guzik, C., Wadhera, A., & Naik, H. (2023). Increased Doses of Adalimumab are Associated With Clinical Improvement of Hidradenitis Suppurativa. Journal of Drugs in Dermatology, 22(6), 615-618. https://doi.org/10.36849/jdd.6868

Vancouver

Williams J, Guzik C, Wadhera A, Naik H. Increased Doses of Adalimumab are Associated With Clinical Improvement of Hidradenitis Suppurativa. Journal of Drugs in Dermatology. 2023;22(6):615-618. doi:10.36849/jdd.6868

BibTeX
@article{Williams2023,
  author = {Williams, Jazzmin and Guzik, Claudia and Wadhera, Akhil and Naik, Haley},
  title = {Increased Doses of Adalimumab are Associated With Clinical Improvement of Hidradenitis Suppurativa},
  journal = {Journal of Drugs in Dermatology},
  year = {2023},
  volume = {22},
  number = {6},
  pages = {615--618},
  doi = {10.36849/jdd.6868}
}
Kostenlos starten →